Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

Virology
Neil ChristensenJ W Kreider

Abstract

Antibodies reactive to HPV types 6 and 11 were tested in ELISA and HPV-11 neutralization assays to determine whether these closely related types shared cross-reactive neutralizing epitopes. A series of HPV-11 neutralizing monoclonal antibodies (N-MAbs) that targeted conformational epitopes on infectious HPV-11 and HPV-11 L1 virus-like particles (VLPs) were tested for type-specificity of reactivity using intact HPV-6 L1 VLPs. Polyclonal antisera generated against intact HPV-6 L1 VLPs were also tested for HPV-11 neutralizing capacity using the athymic mouse xenograft system. The results demonstrated that conformationally dependent neutralizing epitopes on HPV-11 were very type-specific. Three of the four HPV-11 N-MAbs were negative for binding to HPV-6 L1 VLP, and the fourth demonstrated binding to HPV-6 L1 VLPs that was several orders of magnitude weaker than its binding to HPV-11 L1 VLP. The polyclonal anti-HPV-6 L1 VLP antiserum was only partially protective against HPV-11 infectivity even at a low dilution of 1:100. In contrast, polyclonal anti-HPV-11 L1 VLP antiserum was completely protective at dilutions greater than 1:10,000.

Citations

Sep 23, 2006·Nature Reviews. Cancer·Richard Roden, T-C Wu
Apr 4, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M Y TjiongN Van Der Vange
Sep 22, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M E ScheurerK Adler-Storthz
Dec 1, 1996·Genitourinary Medicine·I H Frazer
Mar 8, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Beibei LuAnna R Giuliano
Nov 3, 2009·BMC Public Health·Andrea M AnonychukNadia Demarteau
Sep 14, 2007·BMC Biotechnology·Thomas O KohlEdward P Rybicki
Mar 26, 2010·Journal of Translational Medicine·Nicolas CombelasAntoine Touzé
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·H L GreenstoneJ T Schiller
Mar 11, 2005·Expert Opinion on Emerging Drugs·Neil D Christensen
Apr 2, 2002·The Journal of Investigative Dermatology. Symposium Proceedings·A B JensonS Ghim
Sep 22, 2009·La Presse médicale·Christiane MouginPierre Coursaget
Aug 13, 2008·Vaccine·Eliav Barr, Heather L Sings
Jun 18, 2009·Protein Science : a Publication of the Protein Society·Maxime J J FleuryPierre Coursaget
Aug 30, 2006·Virus Research·Arvind VarsaniEdward P Rybicki
Jul 13, 2006·Antiviral Research·Robert Snoeck
Oct 13, 2005·Vaccine·Margaret Stanley
Dec 20, 2007·The Journal of General Virology·Raeda Z RizkMichael Pawlita
Dec 1, 2001·Expert Opinion on Biological Therapy·J T Schiller, D R Lowy
Apr 23, 2005·American Journal of Obstetrics and Gynecology·Kurt HeimReinhard Höpfl
Mar 14, 2000·Seminars in Cancer Biology·F Breitburd, P Coursaget
Mar 14, 2000·Seminars in Cancer Biology·J Dillner
Mar 12, 2002·Virology·Daniela Tornese BuonamassaGiuliano Bensi
Jul 1, 2008·Journal of Molecular Biology·Santanu MukherjeeAdam Zlotnick
Jul 21, 1997·Virology·M MüllerL Gissmann

❮ Previous
Next ❯